Digital health company Oviva hauls in $12 mln Series A

Digital health company Oviva has secured $12 million in Series A funding. The investors were Albion Capital, Eight Roads Ventures, F-Prime Capital Partners, Partech Ventures and Walking Ventures.


Oviva, a digital health company that is seeking to revolutionise the treatment of health conditions relating to diet with technology, has raised $12m in Series A funding. Albion Capital, Eight Roads Ventures, F-Prime Capital Partners, Partech Ventures and Walking Ventures all participated in the round.

Oviva’s technology and nutritional treatment programmes were designed and tested by specialist clinicians and healthcare experts, with the ambition to dramatically increase patients’ access to tailored and effective treatments for diet-related conditions such as type 2 diabetes, obesity, and food allergies. It uses virtual clinics and high frequency follow up to increase system capacity and improve clinical outcomes, lowering the cost of care. Its app allows patients to message their dietitian directly and self-record their food intake, weight, and activity, giving patients personalised support without the hassle of having to attend regular group sessions or clinical appointments.

Oviva was founded in 2014 in Switzerland and has already helped over 20’000 patients across the UK, Switzerland and Germany to improve their health, and works alongside professional bodies for dietitians including the British Dietetic Association and German Society for Nutrition. Oviva will use this capital to expand its operations across Europe and further develop its product to better serve the millions of patients outside the current community dietetics services.

Oviva has recently been selected as one of five digital providers for the NHS England Digital Diabetes Prevention Programme. The Oviva Diabetes Prevention Programme has the potential to significantly reduce the number of new diagnoses of type 2 diabetes each year in England and save millions of pounds for the NHS, helping patients to avoid complications of diabetes such as eye, kidney and heart disease.

Lucy Jones, Head of Dietetics for Oviva in the UK, commented: “Behaviour change is the safest and most cost-effective way of both preventing and managing diet related health conditions such as type 2 diabetes and obesity. With our technology, patients are empowered to take a leading role in managing their health. Their communication using the technology allows the dietitian more understanding into their health and lifestyle who are then enabled to deliver care focused on the patient’s needs and priorities.’

Kai Eberhardt, CEO and Co-founder of Oviva added: “Several sophisticated and complicated health systems are welcoming our model. The key to this for us are proven benefits to patients and providers from the technology. With the additional funding, we can refine our systems and gain deeper insights into the most successful techniques to help people change their behaviour.”

About Oviva – Oviva is a provider of technology enabled dietetic services for diet related health conditions such as type 2 diabetes, obesity and heart disease. The incorporation of technology into Oviva’s services is designed to strengthen relationships between patients and dietitians, to improve patient outcomes and reduce costs. Oviva was founded in Switzerland by an interdisciplinary team from medicine and technology who saw the challenges patients had in receiving accessible, tailored and effective treatment from a dietitian. Backed by an international investor syndicate Oviva has expanded from Switzerland into the UK and Germany. For more information, visit